Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Sign Up to like & getrecommendations! Published in 2017 at "Mayo Clinic Proceedings"
DOI: 10.1016/j.mayocp.2016.10.009
Abstract: Objective To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL‐SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). Patients and Methods ACTIVExtend, an extension of ACTIVE,… read more here.
Keywords: followed months; risk; treatment; aln ... See more keywords
CT-guided percutaneous implantation of 125I particles in treatment of early lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd-20-2666
Abstract: Background To analyze the efficacy of computed tomography (CT)-guided implantation of 125I radioactive particles in treatment of early lung cancer. Methods Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small… read more here.
Keywords: patients followed; lung cancer; followed months; months procedure ... See more keywords